Search Results

Oxford Nanopore Technologies announced the launch of a new Pharmacogenomics Beta Program to advance personalised medicine, combining Twist Bioscience’s next generation sequencing target enrichment technology with Oxford Nanopore’s sequencing platform.

Oxford Nanopore Technologies plc, the company delivering a new generation of nanopore-based molecular sensing technology, and SeqOne, the leading AI-driven genomic decision support software, announced a new partnership enabling end-to-end analytical workflows from sample to report, focusing on rare diseases in the short-term and oncology in the longer-term.

Oxford Nanopore Technologies announced the early access launch of its all-in-one desk top sequencing device, the PromethION 2 Integrated to complete its PromethION product range.

Oxford Nanopore Technologies plc, the company delivering a new generation of nanopore-based molecular sensing technology, and Saphetor, the next generation sequencing data analysis company, announce a new partnership to support the comprehensive analysis of nanopore sequencing data and to enable end-to-end workflows.

Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for undisclosed cancer targets.